Gabelli & Co Investment Advisers’s AstraZeneca AZN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-9,850	Closed	-$555K	–	170
2016 Q1	$555K	Hold	9,850	–	–	0.07%	98
2015 Q4	$669K	Hold	9,850	–	–	0.08%	103
2015 Q3	$627K	Hold	9,850	–	–	0.09%	99
2015 Q2	$628K	Sell	9,850 -21,800	-69%	-$1.49M	0.09%	101
2015 Q1	$2.17M	Buy	31,650 +600	+2%	+$41.7K	0.36%	48
2014 Q4	$2.19M	Sell	31,050 -1,000	-3%	-$71.6K	0.31%	49
2014 Q3	$2.29M	Hold	32,050	–	–	0.37%	65
2014 Q2	$2.38M	Buy	+32,050	New	+$2.32M	0.51%	50

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Gabelli & Co Investment Advisers's AZN Position: Q2 2016 in Review

Gabelli & Co Investment Advisers sold out of AstraZeneca (AZN) in Q2 2016, closing a stake of 9,850 shares — an estimated $555K sold.

Gabelli & Co Investment Advisers first reported a position in AZN in Q2 2014 and held it in 8 quarters. The position peaked at $2.38M in Q2 2014. 398 funds tracked by Wall St. Rank hold AZN as of Q2 2016.

Gabelli & Co Investment Advisers reported no remaining AstraZeneca position as of Q2 2016 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 9,850 AstraZeneca shares in Q2 2016, an estimated $555K.
Gabelli & Co Investment Advisers first reported a position in AstraZeneca in Q2 2014 and held it in 8 quarters.
Gabelli & Co Investment Advisers's AstraZeneca position peaked at $2.38M in Q2 2014.
398 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2016.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2016, filed 4 Aug 2016.